Maravai Lifesciences Holdings (MRVI) Share-based Compensation (2020 - 2026)

Maravai Lifesciences Holdings' Share-based Compensation history runs 7 years deep, the most recent figure standing at $6.7 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 35.18% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $26.5 million, a 7324.52% increase from a year earlier, with the FY2025 full-year figure at $30.2 million, up 2244.52% from the prior year.
• Share-based Compensation fell to $6.7 million in Q1 2026 per MRVI's latest filing, from $29.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $29.7 million in Q4 2025 and bottomed at -$37.6 million in Q4 2024.
• The 5-year median for Share-based Compensation is $8.4 million (2022), against an average of $5.1 million.
• Across the five-year window, Share-based Compensation jumped 674.51% in 2023 and plunged 172.22% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $9.6 million in 2022, then tumbled by 37.9% to $6.0 million in 2023, then plunged by 727.74% to -$37.6 million in 2024, then jumped by 179.05% to $29.7 million in 2025, then sank by 77.3% to $6.7 million in 2026.
• Per Business Quant, the three latest MRVI Share-based Compensation figures stand at $6.7 million (Q1 2026), $29.7 million (Q4 2025), and -$9.9 million (Q2 2025).